Search | OpenScholar

Search results

356 results found

Onset of dyskinesia with adjunct ropinirole prolonged-release or additional levodopa in early Parkinson's disease

Publication: Journal Article

Watts, RL, KE Lyons, R Pahwa, K Sethi, M Stern, RA Hauser, W Olanow, AM Gray, B Adams, and NL Earl. 2010. “Onset of Dyskinesia With Adjunct Ropinirole Prolonged-Release or Additional Levodopa in Early Parkinson’s Disease”. Mov Disord.

Randomized, double-blind, pilot evaluation of intravenous glutathione in Parkinson's disease

Publication: Journal Article

Hauser, RA, KE Lyons, T McClain, S Carter, and D Perlmutter. 2009. “Randomized, Double-Blind, Pilot Evaluation of Intravenous Glutathione in Parkinson’s Disease”. Mov Disord.

Chorea induced by lamotrigine.

Publication: Journal Article

Zesiewicz, TA, KL Sullivan, and RA Hauser. 2006. “Chorea Induced by Lamotrigine.”. J Child Neurol.

Vascular hemichorea/hemiballismus and topiramate.

Publication: Journal Article

Zesiewicz, TA, KL Sullivan, and RA Hauser. 2006. “Vascular Hemichorea/Hemiballismus and Topiramate.”. Movement Disorders.

Long-term evaluation of deep brain stimulation of the thalamus.

Publication: Journal Article

Pahwa, R, KE Lyons, SB Wilkinson, RK Simpson Jr, WG Ondo, RA Hauser, and . 2006. “Long-Term Evaluation of Deep Brain Stimulation of the Thalamus.”. J Neurosurg.

Levetiracetam for stiff-person syndrome: report of 2 patients

Publication: Journal Article

Shimberg, WR, NB Patel, KL Sullivan, RA Hauser, and TA Zesiewicz. 2008. “Levetiracetam for Stiff-Person Syndrome: Report of 2 Patients”. Clin Neuropharmacol.

Optimizing bioavailability in the treatment of Parkinson’s disease.

Publication: Journal Article

Seeberger, LC, and RA Hauser. 2007. “Optimizing Bioavailability in the Treatment of Parkinson’s Disease.”. Neuropharmacology.

Social Security Disability Insurance (SSDI) in Parkinson’s disease.

Publication: Journal Article

Zesiewicz, TA, A Patel-Larson, RA Hauser, and KL Sullivan. 2007. “Social Security Disability Insurance (SSDI) in Parkinson’s Disease.”. Disabil Rehabil.

Levodopa-induced dyskinesia in Parkinson’s disease: epidemiology, etiology, and treatment.

Publication: Journal Article

Zesiewicz, TA, CL Ward, RA Hauser, JL Salemi, S Siraj, MC Wilson, and KL Sullivan. 2007. “Levodopa-Induced Dyskinesia in Parkinson’s Disease: Epidemiology, Etiology, and Treatment.”. Curr Neurol Neurosci Rep.

Open-label pilot study of levetiracetam (Keppra) for the treatment of levodopa-induced dyskinesias in Parkinson’s disease. Movement Disorders 2005;20:1205-1209.

Publication: Journal Article

Zesiewicz, TA, KL Sullivan, JL Maldonado, and RA Hauser. 2005. “Open-Label Pilot Study of Levetiracetam (Keppra) for the Treatment of Levodopa-Induced Dyskinesias in Parkinson’s Disease. Movement Disorders 2005;20:1205-1209.”. Movement Disorders.